


PI3K/mTOR Inhibitor-13

Cat. No.:	HY-153120
CAS No.:	1621718-37-3
Molecular Formula:	C ₂₀ H ₁₃ F ₂ N ₅ O ₃ S
Molecular Weight:	441.41
Target:	PI3K; mTOR
Pathway:	PI3K/Akt/mTOR
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PI3K/mTOR Inhibitor-13 is an orally active dual inhibitor of phosphoinositol 3-kinase (PI3K) and mTOR kinase. PI3K/mTOR Inhibitor-13 has potential applications in sexual diseases, solid tumor and idiopathic pulmonary fibrosis (IPF) ^{[1][2]} .															
In Vitro	PI3K/mTOR Inhibitor-13 (Compound A) (0-2 μM; 48 h) inhibits the proliferation of HFL1 cells with dose-dependent manner ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]															
	Cell Line:	HFL1 cells.														
	Concentration:	0, 0.03125, 0.0125, 0.025, 0.05, 0.0625, 0.1, 0.125, 0.2, 0.25, 0.4, 0.5, 1 and 2 μM.														
	Incubation Time:	48 h.														
	Result:	Showed inhibitory for HFL1 cells.														
	Western Blot Analysis ^[1]															
	Cell Line:	HFL1 cells.														
	Concentration:	200 nM.														
	Incubation Time:	48 h.														
	Result:	Increased the expression of α-SMA/Tubulin.														
In Vivo	Pharmacokinetic (PK) parameters of PI3K/mTOR Inhibitor-13 ^[2]															
	<table border="1"> <thead> <tr> <th>Species</th> <th>Administration manner</th> <th>Dose (mg/kg)</th> <th>T_{1/2} (h)</th> <th>AUC_{last} (ng•h/mL)</th> <th>Cl/F (L/h/kg)</th> <th>V_{ss} (L/kg)</th> <th>F (%)</th> </tr> </thead> <tbody> <tr> <td>Rat</td> <td>Intravenous injection</td> <td>2</td> <td>2.77</td> <td>7069</td> <td>0.29</td> <td>0.85</td> <td>94.75</td> </tr> </tbody> </table>	Species	Administration manner	Dose (mg/kg)	T _{1/2} (h)	AUC _{last} (ng•h/mL)	Cl/F (L/h/kg)	V _{ss} (L/kg)	F (%)	Rat	Intravenous injection	2	2.77	7069	0.29	0.85
Species	Administration manner	Dose (mg/kg)	T _{1/2} (h)	AUC _{last} (ng•h/mL)	Cl/F (L/h/kg)	V _{ss} (L/kg)	F (%)									
Rat	Intravenous injection	2	2.77	7069	0.29	0.85	94.75									

Mice	Intravenous injection	1	5.45	57059	0.02	0.13	79.3
Dog	Intravenous injection	1	0.67	3672	0.27	0.23	108.5
Monkey	Intravenous injection	1	9.70	5978	0.16	0.92	59.8

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Cao S, et al. Pharmaceutical combination or pharmaceutical composition for treatment of fibrotic diseases. World Intellectual Property Organization. WO2020078445.
- [2]. Xi N, et al. Aromatic heterocyclic compounds, pharmaceutical composition containing compounds and application of pharmaceutical composition.China.CN103965199.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA